- Research Fellowship - Mayo Clinic School of Graduate Medical Education (1997-1998), Neurology
- Fellowship - Mayo Clinic School of Graduate Medical Education (1996-1997), Movement Disorders
- Residency - Mayo Clinic School of Graduate Medical Education (1993-1996), Neurology
- Internship - Mayo Clinic School of Graduate Medical Education (1992-1993), Medicine
- Internship - St. James's Hospital (1991-1992), Medicine
- Medical School - University of Dublin
- Other Post Graduate Training - The University of Texas at Dallas (2012-2015), Health Sector Management

Padraig O'Suilleabhain, M.D.
- Neurology
- Movement Disorders
- General Neurology
Biography
Padraig O’Suilleabhain, M.D., is a Professor in the Department of Neurology at UT Southwestern Medical Center. He specializes in the treatment of movement disorders. He also serves as Director of Ambulatory Neurology Services.
After earning both his bachelor’s degree and medical degree at the University of Dublin, Trinity College, Dr. O’Suilleabhain completed a residency in neurology and a fellowship in movement disorders and clinical investigation at the Mayo School of Graduate Medical Education in Rochester, Minnesota.
He is certified by the American Board of Psychiatry and Neurology.
Dr. O’Suilleabhain has been recognized by D Magazine as a “Best Doctor” in Dallas and received the Dystonia Doctors of Excellence Award from the Dystonia Medical Research Foundation. In 2018, he was named a Super Doctor by Texas Monthly.
He is a member of the American Medical Association, the American Academy of Neurology, and the Dallas County Medical Society Community Service Committee. He also is a member of the American Neurological Association, the Texas Neurological Association, and the Movement Disorder Society, among others.
Meet Dr. O'Suilleabhain
Movement Disorders Specialist in Dallas
Neurologist Padraig O’Suilleabhain, M.D., says there’s an art to treating movement disorders patients – one based on science and reliant on training, skill, and experience.
“Because there are commonalities within diseases, but each patient’s health state and life circumstances are unique, a treatment plan combines individual considerations with approaches proven effective in research trials on large numbers of patients.
“We have to use the most up-to-date evidence plus personal judgment based on experience to decide which approach to use and how to administer it to best help this patient in this context,” he says. “That interface between the science and art of medicine is something I really like about my job.”
As a movement disorders specialist and researcher, Dr. O’Suilleabhain treats patients with conditions such as Parkinson’s disease, progressive supranuclear palsy, dystonia, tremor, Tourette’s syndrome, and Huntington’s disease. Movement disorders cause abnormal voluntary or involuntary movements. These are managed with physical therapies, medication, injections, and sometimes surgery.
“I help my patients navigate through these complicated conditions that can cause chronic difficulties and affect their function, physical presentation, and how they feel about themselves,” Dr. O’Suilleabhain says.
Dr. O’Suilleabhain is an expert in the latest treatments for movement disorders. These include injections of botulinum toxin to reduce muscle contractions and associated pain, and deep brain stimulation to help control symptoms.
“We take advantage of the newest treatments available and the research opportunities to help our patients as much as possible,” he says.
As a member of a team of movement disorders specialists at UT Southwestern, Dr. O’Suilleabhain and his colleagues provide a level of care that is hard to find elsewhere. The team is on-call for its patients 24 hours a day and communicates daily with patients through MyChart, UT Southwestern’s secure online communications tool. Dr. O’Suilleabhain says it’s important to him to give his patients the attention and support they need.
In addition to his patient care responsibilities, Dr. O’Suilleabhain is the Medical Director for outpatient neurology services. He recently completed an M.B.A. program with an emphasis on health care management.
Education & Training
Professional Associations & Affiliations
- Texas Neurological Association
- Movement Disorder Society
- Dallas County Medical Society
- American Medical Association
- American Association of Neurologists
Books & Publications
-
Publications
-
Time-frequency analysis of tremors.
O'Suilleabhain PE, Matsumoto JY Brain : a journal of neurology 1998 Nov 121 ( Pt 11) 2127-34 -
Cortical potentials at the frequency of absolute wrist velocity become phase-locked during slow sinusoidal tracking movements.
O'Suilleabhain PE, Lagerlund TD, Matsumoto JY Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1999 Jun 126 4 529-35 -
Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease.
Dewey RB, O'Suilleabhain PE Neurology 2000 Dec 55 11 1753-4 -
Validation for tremor quantification of an electromagnetic tracking device.
O'Suilleabhain PE, Dewey RB Movement disorders : official journal of the Movement Disorder Society 2001 Mar 16 2 265-71 -
Tremor response to polarity, voltage, pulsewidth and frequency of thalamic stimulation.
O'Suilleabhain PE, Frawley W, Giller C, Dewey RB Neurology 2003 Mar 60 5 786-90 -
Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
O'Suilleabhain PE, Bottiglieri T, Dewey RB, Sharma S, Diaz-Arrastia R Movement disorders : official journal of the Movement Disorder Society 2004 Dec 19 12 1403-8 -
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.
Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Neurology 2004 Jul 63 2 301-4 -
Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Bottiglieri T, Diaz-Arrastia R Archives of neurology 2004 Jun 61 6 865-8 -
Clinical course in Parkinson's disease with elevated homocysteine.
O'Suilleabhain PE, Oberle R, Bartis C, Dewey RB, Bottiglieri T, Diaz-Arrastia R Parkinsonism & related disorders 2006 Mar 12 2 103-7 -
Parkinson disease with severe tremor but otherwise mild deterioration.
O'Suilleabhain PE Archives of neurology 2006 Mar 63 3 321-2 -
Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB, Reimold SC, O'Suilleabhain PE Archives of neurology 2007 Mar 64 3 377-80 -
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, The New England journal of medicine 2009 Sep 361 13 1268-78 -
?-Hexachlorocyclohexane levels in serum and risk of Parkinson's disease.
Richardson JR, Roy A, Shalat SL, Buckley B, Winnik B, Gearing M, Levey AI, Factor SA, O'Suilleabhain P, German DC Neurotoxicology 2011 May -
Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues.
O'Bryant SE, Xiao G, Zhang F, Edwards M, German DC, Yin X, Como T, Reisch J, Huebinger RM, Graff-Radford N, Dickson D, Barber R, Hall J, O'Suilleabhain P, Grammas P Journal of Alzheimer's disease : JAD 2014 Jul -
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Smith KM, Eyal E, Weintraub D, JAMA neurology 2015 Jan 72 1 88-95 -
Developing a Deep Brain Stimulation Neuromodulation Network for Parkinson Disease, Essential Tremor, and Dystonia: Report of a Quality Improvement Project.
Dewey RB, O'Suilleabhain PE, Sanghera M, Patel N, Khemani P, Lacritz LH, Chitnis S, Whitworth LA, Dewey RB PloS one 2016 11 10 e0164154 -
A randomized, single ascending dose study of intravenous BIIB092 in healthy participants.
Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M, Alzheimer's & dementia (New York, N. Y.) 2018 4 746-755 -
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T, The Lancet. Neurology 2019 Jun 18 6 549-558 -
Yet another way to lower homocysteine: close the Patent Foramen Ovale
O'Suilleabhain, Padraig Neurology 2021 2 97 55-56 -
Modest increase in plasma homocysteine follows levodopa initiation in Parkinson’s disease.
O’Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R. Movement disorders : official journal of the Movement Disorder Society December 2004 19(12) 1403-8 -
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.
Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Neurology July 2004 63(2) 301-4 -
Movement disorders after head injury: diagnosis and management.
O’Suilleabhain P, Dewey RB Jr. The Journal of head trauma rehabilitation July 2004 19(4) 305-13 -
Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
O’Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, Diaz-Arrastia R. Archives of neurology June 2004 61 (6) 865-8 -
Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes.
Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH The New England journal of medicine 1995 Jun 332 22 1467-74 -
Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease.
Lemack GE, Dewey RB, Roehrborn CG, O'Suilleabhain PE, Zimmern PE Urology 2000 Aug 56 2 250-4 -
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.
McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M Neurology 2016 Dec -
Clinical course in Parkinson’s disease with elevated homocysteine.
O’Suilleabhain PE, Oberle R, Bartis C, Dewey RB Jr, Bottiglieri T, Diaz-Arrastia R. Parkinsonism & related disorders March 2006 12(2) 103-7 -
Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs.
O’Suilleabhain P, Giller C. Movement disorders : official journal of the Movement Disorder Society November 2003 18(11) 1378-81 -
Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson’s disease.
Defreitas GA, Lemack GE, Zimmern PE, Dewey RB, Roehrborn CG, O’Suilleabhain PE. Urology October 2003 62(4) 651-5 -
Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease.
O'Suilleabhain PE, Dewey RB Archives of neurology 2002 Jun 59 6 986-9 -
Elevated serum pesticide levels and risk of Parkinson disease.
Richardson JR, Shalat SL, Buckley B, Winnik B, O'Suilleabhain P, Diaz-Arrastia R, Reisch J, German DC Archives of neurology 2009 Jul 66 7 870-5 -
Huntington chorea presenting with motor neuron disease.
Sadeghian H, O'Suilleabhain PE, Battiste J, Elliott JL, Trivedi JR Archives of neurology 2011 May 68 5 650-2 -
Parkinson disease with severe tremor but otherwise mild deterioration.
O’Suilleabhain PE. Archives of neurology March 2006 63(3) 321-2 -
Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB 2nd, Reimold SC, O’Suilleabhain PE. Archives of neurology March 2007 64(4) 377-80 -
Levodopa elevates homocysteine: is this a problem?
O’Suilleabhain P, Diaz-Arrastia R. Archives of neurology May 2004 61(5) 633-4 -
Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson's disease.
Defreitas GA, Lemack GE, Zimmern PE, Dewey RB, Roehrborn CG, O'Suilleabhain PE Urology 2003 Oct 62 4 651-5 -
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O'Suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benge M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C, Journal of clinical medicine 2020 Nov 9 11
-
Time-frequency analysis of tremors.
Research
- SPECT scan diagnosis of Parkinson disease
- Huntington disease disease modification
- Deep brain stimulation for treatment of tremor
- Botulinum toxin efficacy
Clinical Focus
- Movement Disorders
- General Neurology
Q&A by Dr. O'Suilleabhain
Links
Results: 2 Locations
Neurology
at UT Southwestern Medical Center at Richardson/Plano 3030 Waterview Parkway, 1st FloorRichardson, Texas 75080 972-669-7181 Directions to Neurology
Neurology Clinic - Movement Disorders
at James W. Aston Ambulatory Care Center 5303 Harry Hines Blvd., 8th FloorDallas, Texas 75390 214-645-8800 Directions to Neurology Clinic - Movement Disorders Parking Info for Neurology Clinic - Movement Disorders